Bacterial targeted tumour therapy-dawn of a new era

Cancer Letters

Volumn 259, Issue 1, 2008, Pages 16-27

  Wei, Ming Q ^a,b   Mengesha, Asferd ^c   Good, David ^a,b   Anné, Jozef ^d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Anaerobic bacteria; Cancer therapy; Genetic modification; Group II intron; Hypoxia; Plasmid; Solid tumour

Indexed keywords

ANTIMITOTIC AGENT; COBALT 60; FLUCYTOSINE; FLUOROURACIL; PROBIOTIC AGENT;

ANAEROBIC BACTERIUM; BIFIDOBACTERIACEAE; CANCER THERAPY; CLINICAL TRIAL; CLOSTRIDIUM; EHRLICH ASCITES TUMOR; ELECTROPORATION; GENETIC ENGINEERING; GLIOBLASTOMA; HUMAN; INTRON; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SHORT SURVEY; SOLID TUMOR; TUMOR CELL DESTRUCTION;

BACTERIA (MICROORGANISMS); CLOSTRIDIA; CLOSTRIDIUM; CLOSTRIDIUM NOVYI; MYCOBACTERIUM BOVIS BCG;

EID: 37049011374     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.10.034     Document Type: Review

References (89)

1. Nowotny A. Antitumour effects of endotoxins. In: Berry L.J. (Ed). Handbook of endotoxin, cellular biology of endotoxin (1985), Elsevier Science Inc., New York
2. Rohdenburg G. Fluctuations in the growth energy of malignant tumours in man, with especial reference to spontaneous recession. J. Cancer Res. 3 (1918) 193-225
3. Boyd W. The Spontaneous Regression of Cancer (1966), Charles C Thomas, Springfield, IL
4. Everson T., and Cole W. Spontaneous Regression of Cancer (1968), JB Saunders & Co., Philadelphia
5. Stephenson Jr. H.E., Delmez J.A., Renden D.I., Kimpton R.S., Todd P.C., Charron T.L., and Lindberg D.A. Host immunity and spontaneous regression of cancer evaluated by computerized data reduction study. Surg. Gynecol. Obstet. 133 (1971) 649-655
6. G.B. Challis, H.J. Stam, The spontaneous regression of cancer, A review of cases from 1900 to 1987, Acta Oncol. 29 (1990) 545-550.
7. Cole W.H. Efforts to explain spontaneous regression of cancer. J. Surg. Oncol. 17 (1981) 201-209
8. Query 2004. 'case report'[all fields] and ('spontaneous resolution'[all fields] or 'spontaneous regression'[all fields] or 'spontaneous remission'[all fields]) and ('carcinoma'[mesh terms] or carcinoma[text word]) or tumour[text word] or tumour[text word] or 'neoplasms'[mesh terms] or cancer[text word]) and ('1987'[pdat] '2003'[pdat]), PubMed 2004.
9. Minton N.P. Clostridia in cancer therapy. Nat. Rev. Microbiol. 1 (2003) 237-242
10. W. Busch, Aus der sitzung der medicinischen section vom 13.November 1867, Berliner Klinische Wochenschrift 5 (1868) 137.
11. Fehleisen V. Ueber die zuchtung der erysipelkokken auf kunstlichem nahrboden und ihreuebertragbarkeit auf den menschen. Dtsch. Med. Wochenschr. 8 (1882) 553-554
12. W.B. Coley, The treatment of malignant tumors by repeated inoculations of erysipelas, With a report of ten original cases, 1893, Clin. Orthop. Relat. Res. (1991) 3-11.
13. Coley W.B. A preliminary note on the treatment of inoperable sarcoma by the toxic products of erysipelas. The Post-Graduate 8 (1893) 278-286
14. Coley W.B. Treatment of inoperable malignant tumours with the toxines of erysipelas and the bacillus prodigiosus. Trans. Am. Surg. Ass. 12 (1894) 50-66
15. Coley W.B. Treatment of inoperable malignant tumours with the toxins of erysipelas and the bacillus prodigiosus. Trans. Am. Surg. Ass. 12 (1894) 183-212
16. Connell H. The study treatment of cancer by proteolytic enzymes, a preliminary report. Can. Med. Ass. J. 33 (1935) 364-370
17. Morales A., Eidinger D., and Bruce A.W. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumours, 1976. J. Urol. 167 (2002) 891-893 discussion 893-895
18. Shintani Y., Sawada Y., Inagaki T., Kohjimoto Y., Uekado Y., and Shinka T. Intravesical instillation therapy with bacillus Calmette-Guerin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guerin immunotherapy. Int. J. Urol. 14 (2007) 140-146
19. Vaupel P., Kelleher D.K., and Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin. Oncol. 28 (2001) 29-35
20. Kopp-Hoolihan L. Prophylactic and therapeutic uses of probiotics: a review. J. Am. Diet. Assoc. 101 (2001) 229-238 quiz 239-241
21. Tamime A.Y. Fermented milks: a historical food with modern applications - a review. Eur. J. Clin. Nutr. 56 Suppl. 4 (2002) S2-S15
22. Kimura N.T., Taniguchi S., Aoki K., and Baba T. Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res. 40 (1980) 2061-2068
23. Wang L., Pan L., Shi L., Sun Y., Zhang Y., and Zhou D. Roles of bifidobacterium on prevention of experimental colorectal carcinoma and induction of apoptosis. Zhonghua Yu Fang Yi Xue Za Zhi 33 (1999) 337-339
24. Graham F.O., and Coleman P.N. Infection of a secondary carcinoma by Salmonella montevideo. Br. Med. J. 1 (1952) 1116
25. Giel C.P. Abscess formation in a pheochromocytoma; report of a case due to Salmonella typhimurium. N. Engl. J. Med. 251 (1954) 980-982
26. Pawelek J.M., Low K.B., and Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 57 (1997) 4537-4544
27. Soghomonyan S.A., Doubrovin M., Pike J., Luo X., Ittensohn M., Runyan J.D., Balatoni J., Finn R., Tjuvajev J.G., Blasberg R., and Bermudes D. Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK. Cancer Gene Ther. 12 (2005) 101-108
28. Li Z., Lang W., Runyan J.D., Luo X., and Clairmont C. Tissue distribution and in vivo expression of cytosine deamionase by TAPETCD, a genetically engineered strain of Salmonella typhimurium as an antitumour vector. Amer. Assoc. Cancer Res. 42 (2001) 687
29. Lin S., Spinka T., and Le T. Tumour-directed delivery and amplification of tumour-necrosis factor-alpha by attenuated Salmonella typhimurium. Clin. Cancer Res. 5 (1999) 3822s
30. Belcourt M., Penketh P.G., Hodnick W., Pike J., and King I. Expression of the mitomycin C activating enzyme DT-diaphorase in tumour-targeted Salmonella. Amer. Assoc. Cancer Res. 41 (2000) 2972
31. Clairmont C., Troy K., Lu X., Li Z., and Pike J. Expression of colicin E3 by tumour targeted Salmonella, enhances antitumour efficacy. Amer. Assoc. Cancer Res. 41 (2000) 466
32. Lee C.H., Wu C.L., and Shiau Endostatin A.L. Gene therapy delivered by Salmonella choleraesuis in murine tumor models. J. Gene Med. 6 (2004) 1382-1393
33. Lee C.H., Wu C.L., Tai Y.S., and Shiau A.L. Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy. Mol. Ther. 11 (2005) 707-716
34. Lee C.H., Wu C.L., and Shiau A.L. Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model. Cancer Gene. Ther. 12 (2005) 175-184
35. Zhao M., Yang M., Li X.M., Jiang P., Baranov E., Li S., Xu M., Penman S., and Hoffman R.M. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc. Natl. Acad. Sci. USA 102 (2005) 755-760
36. Platt J., Sodi S., Kelley M., Rockwell S., Bermudes D., Low K.B., and Pawelek J. Antitumour effects of genetically engineered Salmonella in combination with radiation. Eur. J. Cancer 36 (2000) 2397-2402
37. Toso J.F., Gill V.J., Hwu P., Marincola F.M., Restifo N.P., Schwartzentruber D.J., Sherry R.M., Topalian S.L., Yang J.C., Stock F., Freezer L.J., Morton K.E., Seipp C., Haworth L., Mavroukakis S., White D., MacDonald S., Mao J., Sznol M., and Rosenberg S.A. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J. Clin. Oncol. 20 (2002) 142-152
38. Nemunaitis J., Cunningham C., Senzer N., Kuhn J., Cramm J., Litz C., Cavagnolo R., Cahill A., Clairmont C., and Sznol M. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. 10 (2003) 737-744
39. Mengesha A., Dubois L., Lambin P., Landuyt W., Chiu R.K., Wouters B.G., and Theys J. Development of a flexible and potent hypoxia-inducible promoter for tumor-targeted gene expression in attenuated Salmonella. Cancer Biol. Ther. 5 (2006) 1120-1128
40. Forbes N.S. Profile of a bacterial tumor killer. Nat. Biotechnol. 24 (2006) 1484-1485
41. Wei M.Q., Ellem K.A., Dunn P., West M.J., Bai C.X., and Vogelstein B. Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours. Eur. J. Cancer 43 (2007) 490-496
42. Parker R.C., Plummber H.C., Siebenmann C.O., and Chapman M.G. Effect of hispolyticus infection and toxin on transplantable mouse tumours. Proc. Soc. Exp. Biol. Med. 66 (1947) 461-465
43. Malmgren R.A., and Flanigan C.C. Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res. 15 (1955) 473-478
44. Möse J.R., and Möse G.Z. Onkolyseversuche mit apathogen, anaerogen sporenbildern am Erhlich-Tumor der maus. Z. Krebsforsch 63 (1959) 63-74
45. Möse J.R. Zur Beeinflussbarkeit verschiedener tiertumoren durch einen apathogenen Clostridienstamm. Z. Krebsforsch. 63 (1960) 447-455
46. Carey R. Clostridial oncolysis in man. Proc. Am. Ass. Cancer Res. 6 (1965)
47. Carey R. Clostridial oncolysis in man. Eur. J. Cancer 3 1967 (1967) 37-46
48. Heppner F., and Mose J.R. The liquefaction (oncolysis) of malignant gliomas by a non pathogenic Clostridium. Acta Neurochir. (Wien.) 42 (1978) 123-125
49. Heppner F., Tritthart H., and Holzer P. Surgical therapy of traumatic intracerebral hematomas. Wien Med. Wochenschr 128 (1978) 635-636
50. Engelbart K., and Gericke D. Oncolysis by Clostridia. V. Transplanted tumors of the hamster. Cancer Res. 24 (1964) 239-242
51. Thiele E.H., Arison R.N., and Boxer G.E. Oncolysis by clostridia. IV. Effect of nonpathogenic clostridial spores in normal and pathological tissues. Cancer Res. 24 (1964) 234-238
52. Morse S.S. Evolving views of viral evolution: towards an evolutionary biology of viruses. Hist. Philos. Life Sci. 14 (1992) 215-248
53. Gericke D., and Engelbart K. Oncolysis by clostridia. II. Experiments on a tumor spectrum with a variety of clostridia in combination with heavy metal. Cancer Res. 24 (1964) 217-221
54. Thiele E.H., Arison R.N., and Boxer G.E. Oncolysis by clostridia. III. Effects of clostridia and chemotherapeutic agents on rodent tumours. Cancer Res. 24 (1964) 222-233
55. F. Heppner, J.R. Möse, P.W. Ascher, Oncolysis of malignant glioma of the brain, in: Proc. VIIIth Int. Congr. Chemother. (1983) 38-44.
56. Dietzel F., Gericke D., and Konig W. Tumor hyperthermia using high frequency for increase of oncolysis by Clostridium butyricum(M 55). Strahlentherapie 152 (1976) 537-541
57. Dietzel F., and Gericke D. Intensification of the oncolysis by clostridia by means of radio-frequency hyperthermy in experiments on animals - dependence on dosage and on intervals (author's transl). Strahlentherapie 153 (1977) 263-266
58. Dietzel F., Gericke D., and Ruster I. Further progress with oncolysis due to local high frequency hyperthermia, local X-irradiation and apathogenic clostridia. J. Microw. Power 14 (1979) 163-166
59. Mose J.R. Experiments to improve the oncolysis-effect of clostridial-strain M55 (author's transl). Zentralbl. Bakteriol. [Orig A] 244 (1979) 541-545
60. Heppner F. The glioblastoma multiforme: a lifelong challenge to the neurosurgeon. Neurochirurgia (Stuttg) 29 (1986) 9-14
61. Dang L.H., Bettegowda C., Huso D.L., Kinzler K.W., and Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumours. Proc. Natl. Acad. Sci. USA 98 (2001) 15155-15160
62. Agrawal N., Bettegowda C., Cheong I., Geschwind J.F., Drake C.G., Hipkiss E.L., Tatsumi M., Dang L.H., Diaz Jr. L.A., Pomper M., Abusedera M., Wahl R.L., Kinzler K.W., Zhou S., Huso D.L., and Vogelstein B. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc. Natl. Acad. Sci. USA 101 (2004) 15172-15177
63. Bettegowda C., Dang L.H., Abrams R., Huso D.L., Dillehay L., Cheong I., Agrawal N., Borzillary S., McCaffery J.M., Watson E.L., Lin K.S., Bunz F., Baidoo K., Pomper M.G., Kinzler K.W., Vogelstein B., and Zhou S. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc. Natl. Acad. Sci. USA 100 (2003) 15083-15088
64. Schlechte H., and Elbe B. Recombinant plasmid DNA variation of Clostridium oncolyticum - model experiments of cancerostatic gene transfer. Zentralbl. Bakteriol. Mikrobiol. Hyg. [A] 268 (1988) 347-356
65. Liu S.C., Minton N.P., Giaccia A.J., and Brown J.M. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther. 9 (2002) 291-296
66. Theys J., Pennington O., Dubois L., Anlezark G., Vaughan T., Mengesha A., Landuyt W., Anne J., Burke P.J., Durre P., Wouters B.G., Minton N.P., and Lambin P. Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br. J. Cancer 95 (2006) 1212-1219
67. Fox M.E., Lemmon M.J., Mauchline M.L., Davis T.O., Giaccia A.J., Minton N.P., and Brown J.M. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Ther. 3 (1996) 173-178
68. Theys J., Landuyt A.W., Nuyts S., Van Mellaert L., Lambin P., and Anne J. Clostridium as a tumor-specific delivery system of therapeutic proteins. Cancer Detect. Prev. 25 (2001) 548-557
69. Theys J., Landuyt W., Nuyts S., Van Mellaert L., Bosmans E., Rijnders A., Van Den Bogaert W., van Oosterom A., Anne J., and Lambin P. Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas. FEMS Immunol. Med. Microbiol. 30 (2001) 37-41
70. Minton N.P., Mauchline M.L., Lemmon M.J., Brehm J.K., Fox M., Michael N.P., Giaccia A., and Brown J.M. Chemotherapeutic tumour targeting using clostridial spores. FEMS Microbiol. Rev. 17 (1995) 357-364
71. Barbe S., Van Mellaert L., Theys J., Geukens N., Lammertyn E., Lambin P., and Anne J. Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment. FEMS Microbiol. Lett. 246 (2005) 67-73
72. Theys J., Nuyts S., Landuyt W., Van Mellaert L., Dillen C., Bohringer M., Durre P., Lambin P., and Anne J. Stable Escherichia coli-Clostridium acetobutylicum shuttle vector for secretion of murine tumor necrosis factor alpha. Appl. Environ. Microbiol. 65 (1999) 4295-4300
73. Lambin P., Nuyts S., Landuyt W., Theys J., De Bruijn E., Anne J., Van Mellaert L., and Fowler J. The potential therapeutic gain of radiation-associated gene therapy with the suicide gene cytosine deaminase. Int. J. Radiat. Biol. 76 (2000) 285-293
74. Lemmon M.J., van Zijl P., Fox M.E., Mauchline M.L., Giaccia A.J., Minton N.P., and Brown J.M. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. 4 (1997) 791-796
75. Michel F., Jacquier A., and Dujon B. Comparison of fungal mitochondrial introns reveals extensive homologies in RNA secondary structure. Biochimie 64 (1982) 867-881
76. Peebles C.L., Perlman P.S., Mecklenburg K.L., Petrillo M.L., Tabor J.H., Jarrell K.A., and Cheng H.L. A self-splicing RNA excises an intron lariat. Cell 44 (1986) 213-223
77. Ferat J.L., and Michel F. Group II self-splicing introns in bacteria. Nature 364 (1993) 358-361
78. Martinez-Abarca F., and Toro N. Group II introns in the bacterial world. Mol. Microbiol. 38 (2000) 917-926
79. Dai L., and Zimmerly S. Compilation and analysis of group II intron insertions in bacterial genomes: evidence for retroelement behavior. Nucleic Acids Res. 30 (2002) 1091-1102
80. Dai L., and Zimmerly S. ORF-less and reverse-transcriptase-encoding group II introns in archaebacteria, with a pattern of homing into related group II intron ORFs. RNA 9 (2003) 14-19
81. Toor N., Hausner G., and Zimmerly S. Coevolution of group II intron RNA structures with their intron-encoded reverse transcriptases. RNA 7 (2001) 1142-1152
82. Cui X., Matsuura M., Wang Q., Ma H., and Lambowitz A.M. A group II intron-encoded maturase functions preferentially in cis and requires both the reverse transcriptase and X domains to promote RNA splicing. J. Mol. Biol. 340 (2004) 211-231
83. Curcio M.J., and Belfort M. Retrohoming: cDNA-mediated mobility of group II introns requires a catalytic RNA. Cell 84 (1996) 9-12
84. Cousineau B., Lawrence S., Smith D., and Belfort M. Retrotransposition of a bacterial group II intron. Nature 404 (2000) 1018-1021
85. Frazier C.L., San Filippo J., Lambowitz A.M., and Mills D.A. Genetic manipulation of Lactococcus lactis by using targeted group II introns: generation of stable insertions without selection. Appl. Environ. Microbiol. 69 (2003) 1121-1128
86. Chen Y., McClane B.A., Fisher D.J., Rood J.I., and Gupta P. Construction of an alpha toxin gene knockout mutant of Clostridium perfringens type A by use of a mobile group II intron. Appl. Environ. Microbiol. 71 (2005) 7542-7547
87. Heap J.T., Pennington O.J., Cartman S.T., Carter G.P., and Minton N.P. The ClosTron: a universal gene knock-out system for the genus Clostridium. J. Microbiol. Methods 70 (2007) 452-464
88. Metharom P., Ellem K.A.O., and Wei M.Q. Gene transfer to dendritic cells induced a protective immunity against melanoma. Cell. Mol. Immunol. 2 4 (2005) 281-287
89. Wei M.Q., Metharom P., Ellem K.A.O., and Barth S. Search for "weapons of mass destruction" for cancer-immuno/gene therapy comes of age. Cell. Mol. Immunol. 2 5 (2005) 351-357